List of Excipients in Branded Drug VEMLIDY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Gilead Sciences Inc	VEMLIDY	tenofovir alafenamide	61958-2301	CELLULOSE, MICROCRYSTALLINE
Gilead Sciences Inc	VEMLIDY	tenofovir alafenamide	61958-2301	CROSCARMELLOSE SODIUM
Gilead Sciences Inc	VEMLIDY	tenofovir alafenamide	61958-2301	FERRIC OXIDE YELLOW

Vemlidy Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Vemlidy is a low-dose, film-coated tablet containing 25 mg of tenofovir alafenamide fumarate (TAF) for chronic hepatitis B virus infection. Its excipient strategy is built around direct-compression manufacturability, tablet robustness, rapid disintegration, and protection of a moisture-sensitive low-dose drug substance. The principal commercial opportunities are generic formulation development, excipient supply, moisture-control packaging, pediatric dosage-form innovation, and differentiated TAF products that preserve bioavailability while improving administration.

What excipients are used in Vemlidy tablets?

Vemlidy 25 mg tablets contain a conventional immediate-release tablet platform. The FDA prescribing information identifies the following inactive ingredients.[1]

Functional role	Vemlidy excipient
Diluent and tablet bulk	Lactose monohydrate
Binder and compression aid	Microcrystalline cellulose
Disintegrant	Croscarmellose sodium
Lubricant	Magnesium stearate
Film coating	Hypromellose, titanium dioxide, talc, and iron oxide
Active ingredient	Tenofovir alafenamide fumarate, equivalent to 25 mg TAF

Vemlidy is swallowed as an intact tablet. The FDA label instructs patients not to chew, crush, or split the tablet.[1] That administration requirement creates a potential differentiation opportunity for alternative dosage forms, but it also imposes a higher development burden because any modified product must preserve TAF stability, dissolution, dose uniformity, and systemic exposure.

Why is the excipient load commercially important?

TAF is present at a low dose relative to the total tablet mass. The excipients determine:

• Content uniformity at low drug loading.
• Powder flow and die filling.
• Tablet tensile strength.
• Disintegration and dissolution.
• Moisture uptake and chemical stability.
• Film-coating performance.
• Patient acceptability.
• Manufacturing yield and cost.

The formulation is therefore not a simple high-dose tablet in which the active ingredient dominates tablet behavior. Excipient selection and process control materially influence the commercial performance of a TAF product.

How does Vemlidy’s formulation strategy support manufacturing?

The Vemlidy composition uses widely available pharmaceutical excipients with established regulatory histories. That reduces supply-chain and regulatory risk compared with a formulation based on novel polymers, proprietary lipid systems, or specialized delivery technologies.

Direct-compression and conventional solid-dose advantages

Microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate are compatible with conventional blending, lubrication, compression, and film coating. A generic manufacturer can potentially use a similar process architecture, subject to development data and regulatory requirements.

The central process risks are likely to involve:

1. Uniform distribution of a low-dose active ingredient.
2. Control of lubricant mixing time, because excess magnesium stearate can slow dissolution.
3. Moisture management during blending and coating.
4. Control of tablet hardness without delaying disintegration.
5. Prevention of segregation between TAF fumarate and larger-volume excipients.
6. Film-coat weight and appearance consistency.

A manufacturer seeking a lower-cost process may evaluate roller compaction or wet granulation. Those approaches can improve flow and content uniformity, but they introduce additional exposure to compaction force, moisture, heat, and residence time. For TAF, the preferred process must be established through solid-state, degradation, dissolution, and stability studies.

Moisture and packaging strategy

Moisture control is a commercial differentiator for TAF products. The product label identifies storage at 20°C to 25°C and requires the bottle to remain tightly closed.[1] This packaging instruction indicates that container-closure performance is part of the product’s stability strategy.

Potential packaging configurations include:

• High-density polyethylene bottles with desiccant.
• Induction-sealed bottles.
• Blister packs with high-moisture-barrier films.
• Unit-dose packaging for institutional or public-health channels.
• Child-resistant bottles for retail distribution.

Excipient vendors can capture value through low-moisture grades, tighter particle-size specifications, and co-processed systems that reduce segregation without increasing water activity. Packaging suppliers also have an opportunity to offer validated moisture-barrier systems for generic TAF tablets.

What formulation opportunities exist around Vemlidy?

The strongest formulation opportunities involve administration, stability, and patient access rather than a simple substitution of one standard diluent for another.

Lactose-free formulations

Vemlidy uses lactose monohydrate.[1] A lactose-free generic or follow-on formulation could replace lactose with mannitol, dibasic calcium phosphate, anhydrous lactose, or a co-processed cellulose-based excipient.

A lactose-free product could have commercial value for:

• Patients with lactose intolerance.
• Hospital formularies seeking simplified excipient policies.
• Markets where lactose-free labeling has commercial importance.
• Contract manufacturing customers that standardize on non-lactose platforms.

The change would require comparative dissolution, stability, impurity, and bioequivalence work. Replacing lactose can alter powder density, water activity, compaction behavior, and tablet disintegration.

Pediatric and administration-friendly products

Vemlidy is approved for chronic HBV treatment in adults and pediatric patients meeting the applicable age and weight criteria.[1] The intact-tablet instruction leaves room for dosage-form innovation.

Potential products include:

• Mini-tablets.
• Orally disintegrating tablets.
• Granules for sprinkling on soft food.
• Sachets containing dispersible granules.
• Oral suspensions.
• Lower-strength tablets for weight-based dosing.

Pediatric products face a narrow design window. TAF has a low dose, so dose uniformity is technically manageable, but taste masking and chemical stability become more important in liquid or multiparticulate systems. A suspension may also create challenges involving sedimentation, preservative selection, container compatibility, and in-use stability.

A pediatric formulation could be protected through formulation patents, manufacturing claims, taste-masking claims, or method-of-use claims. Those rights would be distinct from the core TAF compound estate and may remain commercially relevant after tablet exclusivity declines.

Alternate film-coating systems

The Vemlidy film coat includes hypromellose, titanium dioxide, talc, and iron oxide.[1] A generic manufacturer could evaluate a fully formulated coating dispersion, a polyvinyl alcohol-based coating, or a titanium-dioxide-free color system.

Potential advantages include:

• Lower coating-cycle time.
• Reduced pigment handling.
• Improved color consistency.
• Simplified global regulatory review.
• Compliance with jurisdiction-specific titanium dioxide policies.

The coating must not compromise moisture protection, tablet identification, swallowability, or dissolution. A coating change that appears minor from a formulation perspective can affect stability and product appearance across manufacturing sites.

What generic entry risks exist for Vemlidy?

Generic entry is likely to depend on three factors: regulatory exclusivity, Orange Book-listed patents, and the ability to demonstrate bioequivalence for a low-dose immediate-release product.

FDA regulatory pathway

A conventional tablet equivalent to Vemlidy would generally be developed through an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to address:

• Pharmaceutical equivalence.
• Active-ingredient identity and strength.
• Comparative dissolution.
• Bioequivalence.
• Impurity and degradation profiles.
• Stability.
• Manufacturing controls.
• Labeling consistency.

Excipient differences are permitted in an ANDA when they do not affect safety, efficacy, or bioequivalence. The FDA may require additional justification for novel excipients, unusual levels, or dosage forms intended for pediatric use.[2]

Orange Book and Paragraph IV exposure

The Orange Book identifies listed patents and exclusivity information for approved drug products.[3] A Vemlidy generic applicant may use a Paragraph IV certification against relevant listed patents, creating potential patent litigation and a 30-month stay of approval if the patent holder files suit within the statutory period.

The practical entry scenarios are:

Scenario	Commercial effect
No Paragraph IV challenge	Entry generally waits for patent and exclusivity barriers to expire
Paragraph IV challenge with litigation	Approval may be stayed for up to 30 months, subject to statutory exceptions
First substantially complete Paragraph IV applicant	Potential 180-day generic exclusivity, depending on eligibility and forfeiture rules
Patent settlement	Entry date may be earlier than patent expiry but depends on agreement terms and antitrust review
Formulation-specific challenge	May avoid some claims but remains exposed to non-infringement and validity disputes

A formulation change does not automatically avoid patent risk. Claims may cover TAF compositions, solid forms, pharmaceutical formulations, dosing regimens, or methods of treating HBV.

When does Vemlidy lose exclusivity?

Vemlidy’s original FDA approval occurred in 2016.[4] Its regulatory exclusivity period is not the same as its patent term. New chemical entity exclusivity generally lasts five years from approval, while other exclusivity periods may apply to pediatric studies, new indications, or other qualifying supplements.[5]

Patent expiry depends on the particular U.S. patent, patent-term adjustment, patent-term extension, terminal disclaimers, and Orange Book listing. A commercial launch analysis must therefore distinguish:

• FDA regulatory exclusivity.
• Listed patent expiry.
• Pediatric exclusivity.
• Litigation stays.
• Settlement-based entry dates.
• Global patent terms outside the United States.

The FDA Orange Book and USPTO patent records are the controlling sources for a current U.S. entry timeline.[3,6]

How strong is the patent estate for Vemlidy?

Vemlidy’s patent risk is broader than the tablet excipient composition. The relevant estate can include several layers.

Core active-ingredient and prodrug patents

TAF is a prodrug of tenofovir designed to deliver active tenofovir diphosphate intracellularly at lower circulating tenofovir exposure than tenofovir disoproxil fumarate. Core compound and prodrug patents can create the earliest and strongest barrier to generic substitution.

Formulation patents

Formulation claims may cover:

• TAF fumarate with specified excipient classes.
• Particle-size or polymorph characteristics.
• Stabilized solid dosage forms.
• Specific dissolution profiles.
• Moisture-controlled formulations.
• Pharmaceutical compositions with defined drug-to-excipient ratios.

A generic applicant may attempt to design around a formulation claim by changing the diluent, disintegrant, coating, or manufacturing process. That strategy is only effective if the resulting product avoids literal infringement and the doctrine of equivalents.

Method-of-use patents

Vemlidy is approved for chronic HBV treatment. Method-of-use claims can address patient populations, dosing regimens, renal or hepatic impairment, or treatment sequences. These claims may create litigation exposure even where a generic tablet is compositionally different.

Manufacturing and process patents

Process claims may cover preparation of TAF, salt formation, crystallization, particle engineering, or tablet manufacture. Process patents can raise supply-chain risk when an applicant relies on the same active pharmaceutical ingredient route as the reference product.

Which companies are positioned to challenge Vemlidy?

The competitive field includes:

• Generic pharmaceutical companies developing tenofovir products.
• API manufacturers supplying TAF fumarate.
• Contract development and manufacturing organizations.
• Excipient suppliers with low-moisture and direct-compression platforms.
• Specialty firms developing pediatric or modified-release dosage forms.
• Existing HBV competitors using entecavir, tenofovir disoproxil fumarate, or combination regimens.

Vemlidy competes clinically with tenofovir disoproxil fumarate and entecavir, not only with potential generic TAF tablets. TAF’s commercial proposition is based on antiviral efficacy with lower systemic tenofovir exposure and a renal and bone safety profile that can support physician and payer differentiation.[1,7]

How does Vemlidy compare with competing HBV drugs?

Product	Active ingredient	Dosage form	Excipient opportunity	Commercial positioning
Vemlidy	Tenofovir alafenamide	25 mg film-coated tablet	Lactose-free, pediatric, moisture-barrier, low-cost generic	Lower-dose TAF platform
Viread and generic TDF	Tenofovir disoproxil fumarate	Tablets and other forms by market	Broad generic manufacturing base	Established low-cost competitor
Baraclude and generic entecavir	Entecavir	Tablets and oral solution	Pediatric liquids and low-cost tablets	Established HBV treatment option
TAF generic	Tenofovir alafenamide	Likely immediate-release tablet initially	Excipient substitution and process optimization	Direct substitution opportunity

TAF’s lower dose may reduce API cost per unit, but the product remains sensitive to formulation execution. Generic manufacturers can compete through lower manufacturing cost, simpler packaging, lactose-free positioning, or supply reliability.

What commercial opportunities exist for excipient suppliers?

Low-moisture direct-compression excipients

Suppliers can develop grades of microcrystalline cellulose, mannitol, lactose alternatives, and co-processed excipients with:

• Controlled moisture content.
• Narrow particle-size distribution.
• High compactability.
• Low segregation tendency.
• Consistent bulk density.
• Strong lot-to-lot performance.

The value proposition is process reliability, not merely lower unit price.

Excipient systems for content uniformity

A pre-engineered excipient blend could combine a diluent, binder, and disintegrant for low-dose TAF tablets. Such a platform may shorten development time and reduce formulation screening. The supplier would need to support extractables, elemental impurities, nitrosamine risk assessments where relevant, and global regulatory documentation.

Moisture-control packaging

Packaging suppliers can target Vemlidy-equivalent products with:

• High-barrier bottle systems.
• Integrated desiccants.
• Unit-dose blister systems.
• Transport-stability solutions for tropical markets.
• Packaging optimized for public-health procurement.

This opportunity is commercially relevant because HBV treatment is distributed across markets with variable temperature and humidity conditions.

Pediatric taste-masking platforms

TAF pediatric products could use ion-exchange resins, polymeric coatings, lipid barriers, or multiparticulate coating technologies. The main development criteria are taste, dose uniformity, release after administration with soft food, and chemical stability during storage.

What licensing and partnership opportunities exist?

The most actionable deal structures are likely to involve:

1. Excipient platform licensing for direct-compression or moisture-controlled tablets.
2. CDMO partnerships for TAF API and finished-dose manufacturing.
3. Pediatric dosage-form licensing.
4. Regional licensing of generic or differentiated TAF products.
5. Packaging technology agreements for climate-sensitive markets.
6. Co-development of fixed-dose HBV combinations.

A generic manufacturer may prefer a formulation and process package that includes excipient grades, compression parameters, dissolution specifications, analytical methods, and stability data. A specialty pharmaceutical company may instead seek rights to a pediatric or administration-friendly dosage form.

Any license involving TAF must address patent ownership, freedom to operate, regulatory data rights, supply commitments, territory, manufacturing-site qualification, and launch timing after patent or settlement restrictions.

What revenue exposure does Vemlidy create?

Vemlidy is commercially important to Gilead’s HBV franchise and contributes recurring revenue from chronic treatment. Exact product revenue varies by reporting period and should be taken from Gilead’s current Form 10-K and quarterly filings.[8]

Revenue erosion after generic entry is likely to follow a staged pattern:

• Initial erosion from authorized or first generic competition.
• Greater price pressure as multiple ANDA approvals occur.
• Formulary substitution and channel-driven volume migration.
• Residual branded demand from patients and physicians who value continuity.
• Continued protection for pediatric, combination, or differentiated formulations where applicable.

TAF’s lower-dose formulation may support competitive API economics, but branded price retention depends on the strength of clinical differentiation, payer coverage, and the timing of generic approvals.

What is the best commercial strategy for a Vemlidy follow-on product?

The highest-probability strategy is a conventional immediate-release generic tablet with a controlled excipient and packaging platform. The highest-value differentiated strategy is a pediatric or administration-friendly TAF dosage form.

Strategy	Development complexity	Commercial upside	Main risk
Conventional generic tablet	Low to moderate	High volume, lower margin	Patent and price competition
Lactose-free tablet	Moderate	Formulary and patient differentiation	Bioequivalence and stability
Blister-pack product	Moderate	Better moisture control and global distribution	Packaging cost
Pediatric mini-tablet or granule	High	Lifecycle extension and specialty pricing	Taste, stability, regulatory burden
Oral suspension	High	Administration flexibility	Dose uniformity and in-use stability
Fixed-dose combination	High	Broader regimen positioning	Combination patent and clinical requirements

Key Takeaways

• Vemlidy uses a conventional excipient platform based on lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and a hypromellose-based film coat.
• The main technical challenge is low-dose TAF uniformity combined with moisture and stability control.
• Generic manufacturers can pursue excipient substitution, but changes must preserve bioequivalence, dissolution, stability, and tablet performance.
• Lactose-free tablets, pediatric mini-tablets, granules, and improved packaging are the strongest formulation opportunities.
• Patent risk extends beyond excipients to TAF compound, solid-state, formulation, method-of-use, and manufacturing claims.
• The most attractive supplier opportunities are low-moisture direct-compression excipients, co-processed systems, pediatric taste-masking technologies, and high-barrier packaging.
• Commercial value is highest in a conventional low-cost generic tablet for scale or a differentiated pediatric product for lifecycle management.

FAQs

Can Vemlidy tablets be reformulated with mannitol instead of lactose?

Yes, a generic developer can evaluate mannitol or another diluent, but the alternative must support acceptable content uniformity, compression, disintegration, dissolution, stability, and bioequivalence.

Is Vemlidy suitable for an orally disintegrating tablet?

TAF’s low dose makes an orally disintegrating tablet technically feasible, but taste masking, moisture protection, dose uniformity, and rapid-release performance would require dedicated development.

Does a different excipient combination avoid Vemlidy patent infringement?

No. Excipient substitution may avoid a specific formulation claim, but compound, process, solid-form, method-of-use, and equivalents-based infringement risks can remain.

What is the most valuable excipient innovation for TAF products?

A low-moisture, co-processed direct-compression system that improves content uniformity and tablet robustness without slowing dissolution has the clearest broad commercial value.

Could TAF be sold as a pediatric oral liquid?

A pediatric liquid or suspension could be developed, but it would require evidence for chemical stability, preservative performance where applicable, dosing accuracy, palatability, container compatibility, and in-use stability.

References

1. U.S. Food and Drug Administration. (2024). Vemlidy (tenofovir alafenamide) prescribing information. Gilead Sciences, Inc.
2. U.S. Food and Drug Administration. (2019). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2016). FDA approves new treatment for chronic hepatitis B.
5. U.S. Food and Drug Administration. (2023). Small Business Assistance: Frequently Asked Questions for New Drug Product Exclusivity.
6. United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension resources.
7. European Medicines Agency. (2024). Vemlidy: EPAR product information.
8. Gilead Sciences, Inc. (2024). Annual report on Form 10-K.